Aflac Inc.

Strong Financial Performance: Aflac Incorporated reported net earnings per diluted share of $1.98 and adjusted earnings per diluted share of $1.75 for Q1 2026, marking a 6.6% year-over-year increase in adjusted earnings. The company's solid execution on its strategy is contributing to long-term shareholder value.

Sales Growth in Japan: Aflac Japan experienced a substantial 25.5% sales increase in Q1, driven by the success of its new medical product Onsen Tallett and the Miraito cancer insurance product. This growth highlights Aflac Japan's effective marketing and sales transformation initiatives implemented in the previous year.

U.S. Business Stability: Aflac's U.S. operations reported a 2.9% year-over-year increase in sales and maintained a strong premium persistency of 79.3%. Despite challenges in the core agent business, group products are performing well, with a 12.4% sales increase observed in key categories.